MDGL Key Statistics, Chart & Performance
The current stock price of MDGL is 602.21 USD. In the past month the price increased by 2.43%. In the past year, price increased by 92.33%.
MDGL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.21 | 404.36B | ||
| AMGN | AMGEN INC | 15.16 | 178.50B | ||
| GILD | GILEAD SCIENCES INC | 15.29 | 155.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.45 | 116.51B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.52B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 781.76 | 52.67B | ||
| INSM | INSMED INC | N/A | 37.70B | ||
| NTRA | NATERA INC | N/A | 32.49B | ||
| BIIB | BIOGEN INC | 10.44 | 25.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.34 | 21.98B | ||
| INCY | INCYTE CORP | 15.72 | 19.81B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.28B |
Related stock screener links
About MDGL
Company Profile
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania and currently employs 528 full-time employees. The company went IPO on 2007-02-06. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Company Info
MADRIGAL PHARMACEUTICALS INC
200 Barr Harbor Drive, Suite 400
West Conshohocken PENNSYLVANIA 19428 US
CEO: Paul A. Friedman
Employees: 528
Phone: 14043809263
MADRIGAL PHARMACEUTICALS INC / MDGL FAQ
What does MADRIGAL PHARMACEUTICALS INC do?
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania and currently employs 528 full-time employees. The company went IPO on 2007-02-06. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
What is the stock price of MADRIGAL PHARMACEUTICALS INC today?
The current stock price of MDGL is 602.21 USD. The price decreased by -0.1% in the last trading session.
What is the dividend status of MADRIGAL PHARMACEUTICALS INC?
MDGL does not pay a dividend.
What is the ChartMill rating of MADRIGAL PHARMACEUTICALS INC stock?
MDGL has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy MDGL stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MDGL.
What is the expected growth for MDGL stock?
The Revenue of MADRIGAL PHARMACEUTICALS INC (MDGL) is expected to grow by 443.88% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
MDGL Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to MDGL. When comparing the yearly performance of all stocks, MDGL is one of the better performing stocks in the market, outperforming 95.11% of all stocks.
MDGL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MDGL. The financial health of MDGL is average, but there are quite some concerns on its profitability.
MDGL Financial Highlights
Over the last trailing twelve months MDGL reported a non-GAAP Earnings per Share(EPS) of -12.89. The EPS increased by 48.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.22% | ||
| ROE | -46.21% | ||
| Debt/Equity | 0.54 |
MDGL Forecast & Estimates
23 analysts have analysed MDGL and the average price target is 611.04 USD. This implies a price increase of 1.47% is expected in the next year compared to the current price of 602.21.
For the next year, analysts expect an EPS growth of 51.35% and a revenue growth 443.88% for MDGL